Expression Of Visfatin And Its Significances In Endometrial Carcinoma Tissues

Objective:To study the expression of visfatin in human endometrial carcinoma tissues,,atypical hyperplasia,hyperplasia and normal endometrium,so as to explore the role of visfatin on the occurrence and development in endometrial carcinoma and their relationship with clinical pathologic features.Methods:86cases of normal proliferative or secretory endometrium(NE),24cases of hyperplasia of endometrium(HE),25cases of atypical hyperplasia of endometrium (AHE) and164cases of endometrial carcinoma (EC) were from General HosPital of Tianjin Medieal University, the clinical cases were collected and the expressions of visfatin in normal endometrium(NE), hyperplasia of endometrium(HE),atypical hyperplasia of endometrium (AHE) and endometrial carcinoma (EC) were detected by means of immunohistochemical staining. SPSS14.0software was employed to anayze all datas. Comparisons between visfatin expression in EC, AHE, HE, and NE tissues were made using the chi-square (x2) test. Comparisons between tissue visfatin expression and clinicopathologic variables were also made using the x2test or Fisher’s exact test. Kaplan-Meier were used to estimate the association between visfatin expression in EC tissues and overall patient survival. Survival curves were generated using Kaplan-Meier estimates, and the differences between curves was evaluated with the log-rank test. Hazard ratios (HRs) and95%confidence intervals (CIs) computed from multivariate Cox regression models were used to investigate the relationship between clinicopathologic characteristics and survival. P values less than0.05were considered statistically significantResults:1Visfatin protein was detected in tissue samples from patients in the EC. AHE, HE and control NE groups. visfatin expression increased gradually in endometrial tissues as they progressed from NE to HE to AHE and finally to EC(x2=12.603, P＜0.001). More specifically,Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue (P=0.001), whereas there were no significant differences in tissue visfatin expression between EC and HE,patients (P=0.268), EC and AHE patients (P=0.742), AHE and NE patients (P=0.172), or HE and AHE patients (P=0.545)2The positive expression rate of visfatin in endometrial cancer is80.5%, high visfatin expression in EC tissues was significantly associated with advanced tumor stage (P=0.023) and deep myometrial invasion (myometrial invasion≥1/2; P=0.016).3These data suggest a better prognosis for the negative visfatin expression group than the low expression and high expression groups (x2=6.687, P=0.035). This data illustrate a lower trend of recurrence and therefore a better prognosis for the negative expression group than the low expression and high expression groups (x2=8.514,P=0.014;). Using multivariate Cox regression analyses, we found that visfatin expression (HR,1.78;95%CI,1.26-2.52; P=0.001), nonendometrioid histologic subtype (HR,1.56;95%CI,1.09-2.22; P=0.015) and FIGO stage(HR,4.77;95%CI,1.06-21.49; P=0.042) were significant independent predictors of overall survival in EC patientsConclusions:1visfatin expression increased gradually in endometrial tissues as they progressed from NE to HE to AHE and finally to EC.Visfatin may played an essential role of promoting in the progression of endometrial carcinoma.2High visfatin expression in EC tissues was significantly associated with advanced tumor stage and deep myometrial invasion.3There was a better progno-sis for the negative visfatin expression group thanthe low expression and high expression groups. Visfatin expression, nonendometrioid histologic subtype and FIGO stage were significant independent predictors of overall survival in EC patients.Visfatin may be a high risk for EC progression and prognosis which may provide new ideas for the diagnosis and treatment of EC.